| { | |
| "a685d6a19f4c2e6b9544eacd434dd5c34f73a5cc053": "", | |
| "3fe033a7dd25db5c80d2d00e13d984858d95a54e056": "4 days", | |
| "a685d6a19f4c2e6b9544eacd434dd5c34f73a5cc106": "", | |
| "a685d6a19f4c2e6b9544eacd434dd5c34f73a5cc108": "13.6%", | |
| "a685d6a19f4c2e6b9544eacd434dd5c34f73a5cc146": "59 cases enrolled in the present study and the sample size may be not very large", | |
| "5f920af16c06cb8dd2bbaa3438d1f7c698189714004": "5.84", | |
| "23f59bd537c94359cbdae275ff74e20d243b3c09082": "", | |
| "6fb821163ee9be7b103c6dfb326893f360626060083": "5.2 days", | |
| "e39b5cc7c4a5a7b7a8455f1c4997079224e505c1070": "4 (3-7) days", | |
| "4fa8d0dacd193afabf0a7b3602017653ef212742052": "5 days", | |
| "de820a49e22cb0689e1ce97c3e14ba785ae960db009": "2.52 days", | |
| "d0189194bb86dc2d52e761922a8975cd924b7b2e012": "before infectors' symptom onsets", | |
| "043bb949c117470d75b35927b00c73427b2fe598100": "256", | |
| "f12aef8c054b252fb627c716a84e2860efa04bc8104": "", | |
| "de820a49e22cb0689e1ce97c3e14ba785ae960db108": "7.44 days", | |
| "de820a49e22cb0689e1ce97c3e14ba785ae960db132": "7.44 days", | |
| "ad0e6e0b3839fa4403ba506102e07a73056fb4ff169": "", | |
| "55032dde41fe307db9fadd843383229ab13ffdd7087": "4 days", | |
| "ed38aac7595bb9c2a2de585d7dbcb1518253ae03006": "0 to 33 days", | |
| "70965fa642778a0805018fc141f2f48cd341eff2008": "7-day) but significantly shorter than that (9-day) of child cases (P=0.02", | |
| "1600bd1587818a759d585e4498e54ef0f2cac55b008": "7-day) but significantly shorter than that (9-day) of child cases (P=0.02", | |
| "ed38aac7595bb9c2a2de585d7dbcb1518253ae03023": "", | |
| "ed38aac7595bb9c2a2de585d7dbcb1518253ae03033": "", | |
| "ed38aac7595bb9c2a2de585d7dbcb1518253ae03053": "0 to 33 days", | |
| "3312fec1093454dbe709eceab29c6bc2e025c0c639": "7.2 days", | |
| "4b4a9151d0d695b844fe75acd058463c8baf6c10001": "10.50", | |
| "c51c33447498f69ce2dcedf8e7155364ad8912e5001": "10.50", | |
| "4b4a9151d0d695b844fe75acd058463c8baf6c10054": "10.50", | |
| "c51c33447498f69ce2dcedf8e7155364ad8912e5054": "10.50", | |
| "4b4a9151d0d695b844fe75acd058463c8baf6c10078": "10.50", | |
| "c51c33447498f69ce2dcedf8e7155364ad8912e5078": "10.50", | |
| "e77876412ca662a254b36ca91ca875af8010e71a040": "", | |
| "8a358718ddc50ea0b9c4d415a3484645ccddd42f095": "4 days", | |
| "8a358718ddc50ea0b9c4d415a3484645ccddd42f144": "4 days", | |
| "5b720fb7d5349886c404f02122e0b26365e1283b018": "1211", | |
| "52764491d6fe3db5c4c2bdf793882527fe3f4392115": "8\u00b713 days", | |
| "f8f474a4d7942c53a757174a39de5c1c753ba6cb003": "69 hospitalized patients with confirmed SARS-CoV-2 pneumonia without comorbidities and 14,117 normal controls.", | |
| "7321e6805b8bd42782254e34faab2f2c890d299e008": "4 days", | |
| "f8f474a4d7942c53a757174a39de5c1c753ba6cb087": "69 hospitalized patients with confirmed SARS-CoV-2 China CDC official report on February 29, 2020", | |
| "7321e6805b8bd42782254e34faab2f2c890d299e137": "4 days", | |
| "7321e6805b8bd42782254e34faab2f2c890d299e216": "4 days", | |
| "2d4b267c69c49b2e6e28b0abef213e1c84900434052": "5.1 days", | |
| "2d4b267c69c49b2e6e28b0abef213e1c84900434059": "5.1 days", | |
| "6fa8f0d6cf8665e56da562a7f12e622a06eeffcf005": "4.9 days", | |
| "6fa8f0d6cf8665e56da562a7f12e622a06eeffcf062": "4.9 days", | |
| "d671fdebee5bc9a9a2efd1f1b5ca48a6355278c6071": "", | |
| "acd6dfd475fa45e39304c88554307973dbeeb0db005": "7.1", | |
| "72a7b16503937260e08d628e405f3ee79036db3f072": "", | |
| "4b3105f13e1b3f41b9430130061c09049b41f5f5107": "18, 19, 20, 21, 23, 24 , 24 and 32 days) that more than 14 days", | |
| "72a7b16503937260e08d628e405f3ee79036db3f224": "", | |
| "b868c0553d84587f654406d153b0e5c62a43faf7005": "", | |
| "f67079b4158e021cb78bd9b07b1c43fc231458b0006": "5.0%", | |
| "b868c0553d84587f654406d153b0e5c62a43faf7006": "", | |
| "53d3b3070ee38ea1f3b1e6d4f5fda43b329e0d58010": "6.7 days", | |
| "b868c0553d84587f654406d153b0e5c62a43faf7050": "", | |
| "b868c0553d84587f654406d153b0e5c62a43faf7051": "", | |
| "f67079b4158e021cb78bd9b07b1c43fc231458b0052": "92.6%", | |
| "53d3b3070ee38ea1f3b1e6d4f5fda43b329e0d58059": "6.7 days", | |
| "b868c0553d84587f654406d153b0e5c62a43faf7060": "", | |
| "b868c0553d84587f654406d153b0e5c62a43faf7062": "", | |
| "53d3b3070ee38ea1f3b1e6d4f5fda43b329e0d58086": "6.7 days", | |
| "b30758c7b38dc8ae00d01e4ed24a4449e29b15ea007": "6 (IQR, 3-8) days", | |
| "b30758c7b38dc8ae00d01e4ed24a4449e29b15ea076": "6 (IQR, 3-8) days", | |
| "413046a5692fcb7823efb67487cdad137947961e033": "6.4 days", | |
| "b67da0d4f088f0c4dd5f0f997944c180d461c2ed056": "3 and 6 days", | |
| "21158cb22d339533ffb2af631fc4c8b5d445af66000": "Henan of China", | |
| "5f30832ee7df351a642cd0a0b8f200c55963b4a5001": "7.4, 4 and 7 days", | |
| "21158cb22d339533ffb2af631fc4c8b5d445af66017": "", | |
| "21158cb22d339533ffb2af631fc4c8b5d445af66032": "", | |
| "21158cb22d339533ffb2af631fc4c8b5d445af66146": "Fig.5", | |
| "f6200ab2fa4e0436d8e95ffaee0f09e9ac6faeb9051": "5.6 days", | |
| "1ce8c9bd8de5dc091cee01684a1fbdda97547e9f002": "6.4", | |
| "fbb56a9a4434ea13ea8d65f9616d371821b3d69f002": "6.4", | |
| "aceb88f2c61f92eb967d441560f929aa63832a20078": "4\u00b78 days", | |
| "aceb88f2c61f92eb967d441560f929aa63832a20089": "4\u00b78 days", | |
| "27ac2cc83b4097ba927cbe31e474bda08e5e62a7089": "4\u00b78 days", | |
| "4dd9db5e2243c57613f2f183216acc6674541f1c005": "", | |
| "4dd9db5e2243c57613f2f183216acc6674541f1c009": "", | |
| "4dd9db5e2243c57613f2f183216acc6674541f1c042": "", | |
| "4dd9db5e2243c57613f2f183216acc6674541f1c058": "", | |
| "4dd9db5e2243c57613f2f183216acc6674541f1c061": "1 260", | |
| "84ac637cfbd3e70557fef0b3f8065269ed72d420065": "12 days", | |
| "5cebe9fcb93ffc972081088bf971676555163808065": "12 days", | |
| "ac27dcb0b6769e66449e0354dc373101f7793230065": "12 days", | |
| "4dd9db5e2243c57613f2f183216acc6674541f1c082": "67 patients, any reported fever", | |
| "e95423b2ce20955237ed7851f6e5731133a67f9a151": "0.023", | |
| "4dd9db5e2243c57613f2f183216acc6674541f1c151": "", | |
| "51fe36c7096a73a90ddbb86c4c228680168e36e5013": "20\u00b70 days", | |
| "51fe36c7096a73a90ddbb86c4c228680168e36e5065": "20\u00b70 days", | |
| "0e31f2b199e0d39a8402a2c6b69d62444adcf3cc027": "", | |
| "c93981cd1eb50064cf684cea5ac0445518cd3685032": "7.74 d \u00b1 3.22", | |
| "c93981cd1eb50064cf684cea5ac0445518cd3685215": "", | |
| "cf836d2abbbd1802c6567c82f831ec75e91d0f7b004": "15 -64 age group, the median incubation time of 7.00 +1.10 \u22120.90 days", | |
| "cf836d2abbbd1802c6567c82f831ec75e91d0f7b067": "15 -64", | |
| "7d835e7d5f345291a1454773956fc49b540df37a01": "21.7%", | |
| "7d835e7d5f345291a1454773956fc49b540df37a11": "21.7%", | |
| "7d835e7d5f345291a1454773956fc49b540df37a23": "21.7%) individuals were identified as asymptomatic carriers, with a predominant distribution of males (61.0%", | |
| "7d835e7d5f345291a1454773956fc49b540df37a38": "21.7%", | |
| "7d835e7d5f345291a1454773956fc49b540df37a54": "18/83, 21.7%", | |
| "4dd0c041ff25784144ea4f486aa7c1019f0996e954": "", | |
| "b83bcb24bd5e96fd22e9cdeca0d07c78cb021553062": "getting higher and higher", | |
| "d98362e4bb5346d06295b0a4bf01e8b06a4fc163105": "28.6% of infected children.", | |
| "b83bcb24bd5e96fd22e9cdeca0d07c78cb021553118": "", | |
| "d98362e4bb5346d06295b0a4bf01e8b06a4fc163118": "", | |
| "d98362e4bb5346d06295b0a4bf01e8b06a4fc163136": "", | |
| "cea21f0d2923961ef64038d1c4edfec5fc91531b060": "32 laboratory-confirmed COVID-19 patients, including five household/family clusters and four", | |
| "ce8cbaa1c8f104c56ec83be5af64c7ab44d96c7302": "17.9%", | |
| "ce8cbaa1c8f104c56ec83be5af64c7ab44d96c7334": "17.9%", | |
| "010cbf25abce2f72fb027084541c6c4ad55ea38662": "", | |
| "ce8cbaa1c8f104c56ec83be5af64c7ab44d96c7375": "17.9%", | |
| "8388e536ee9a7eab60d3b7f6ae1c01882995f27f015": "29.2%", | |
| "2c611add98c5b907d63ca207167629c5aaab1e1c005": "32.6%", | |
| "2c611add98c5b907d63ca207167629c5aaab1e1c081": "43", | |
| "7fb7797bb5d0c586c8bb69e7583dd3b8f6d8cd84142": "29%", | |
| "29755b498ef7bab4d07c8f627ed10185a853d5b2047": "27.03%) cases were asymptomatic carriers of SARS-CoV-2, 53", | |
| "85b74a989fd539be6f3f51fd8289de9de9b961cc153": "seven", | |
| "0ab1f3cb167781faed7aec5f2b47491c4adc002b153": "", | |
| "2b907ad7909aee89b2a572c34dcded231a62fb8101": "", | |
| "4d51fec02d52d016b90a97ec543798ff9488628023": "", | |
| "1274de68c243bb545a01c33737459c08725f5323093": "8.0%", | |
| "0ed999d64d23d762d0e9bff247267aebe676dc12034": "66.7%", | |
| "8de019b3a49a7a6d4a9f30350956fe5a03e233f3007": "Eighty-three percent of the children were within family clusters of cases, and 19%", | |
| "6adfe4e235d9817cca52d212e9085b87f119ce0b004": "Eleven children (34%) were asymptomatic, among whom six children had normal computed tomographic (CT) scan images", | |
| "06238b83fefbedf8ff094f5781a90516a818aee4012": "44.8%", | |
| "24a0d9f214ed92c962a3047edcf4447dcedb096f026": "44% of transmission prior to symptom onset", | |
| "277dbb9e7b55d3a204f3d8d42a5cb12b636d56c833": "100% positive on the third week after onset and 30% positive 29 days", | |
| "d38ee912aa0c565538bfa396bbb761b0ad2c41a0103": "", | |
| "bf1c37bfdac6c9fad1f8213b78aa86b6969e6267116": "", | |
| "d38ee912aa0c565538bfa396bbb761b0ad2c41a0161": "", | |
| "388b578c809d929866294c7d8e41ad125335a3fc26": "", | |
| "bea70fe78c0eb0fe39a58f6a29d8f068446e1e0430": "10.0 days", | |
| "40b62448cd84a72f8d5de872513e19842ef6bfb430": "10.0 days", | |
| "cae61e0ef3d90a927cc55af2e3c00f6bddc5ea13084": "fecal shedding of viral RNA after clearance of respiratory samples ranged from 1 to 33 days", | |
| "3fc876f22ef9091895f500858f305ac1b83d251314": "", | |
| "3fc876f22ef9091895f500858f305ac1b83d251317": "", | |
| "3fc876f22ef9091895f500858f305ac1b83d251328": "", | |
| "8e916bfec350d065bd0b22df89a8acdc7b86752733": "15.67 \u00b16.68 days in non-ICU group and 22.25 \u00b13.62 days in ICU group.", | |
| "1167414ac8fda26d2e6c6b72d1e50b39cde61e0b011": "97% sensitivity of chest CT", | |
| "cee41f7b445c254c87cb89523098b00a83d6e29f005": "", | |
| "f0f47e5997da53c32b3a1d00afa457804eb0da6d005": "72.73% and 87.50%", | |
| "1335019f565c0d25ee94ec53c9c1e148a84f78aa096": "", | |
| "25a5780b6dfc7b2ddbe2253505b8fdd7335d5384061": "", | |
| "8f0b00db40ef54932f0c7c67f3dd055cbf0cb751008": "97.2%, whereas the sensitivity of initial rRT-PCR was only 83.3%", | |
| "92b398fbc957f2e444932faf5d29a485cd55efad078": "iLACO", | |
| "24e0e8b45bb0cb49460387867461ad59f3af61d6009": "", | |
| "9bd1d79ff52b41dd3cb998d76fe8950b166fa7a3009": "warmer climate and COVID-19 spread rate", | |
| "9bd1d79ff52b41dd3cb998d76fe8950b166fa7a3016": "March 9, 2020", | |
| "42eba2b19039137096fc21237dad069939b3814d037": "1 \u2022 C increase in local temperature reduces new COVID-19 cases per 1 million people by 13%", | |
| "a04c6b0bd79a5ed933d5c2e33335544b76fae59e01": "1\u00b0C and higher", | |
| "2158d545a94abd2940504d78482a3ae22a9a53e4006": "1%", | |
| "637d62684f0b4455942358068752d6057d89ffb5009": "~15%", | |
| "0a5a912957653e9802e4b85eeef8368a2b6765b7005": "", | |
| "f1b2dfa490c3eaea07a8018aeef95019ec5a636029": "r = 0.392", | |
| "7d2b58873813a409380153b8e9c66788a69bd081293": "", | |
| "4286f677e70d11189b992602bfc2eaaca379638f070": "per 1 unit increase of temperature and absolute humidity were related to the decreased COVID-19 death counts in lag 3 and lag 5", | |
| "d1348f748ccf419d597f94238cb36c242e2f148d016": "a decrease in the rate of progression of COVID-19 with the arrival of spring and summer in the north hemisphere", | |
| "74b62ba69fdc892e416fc5315366dd67bc50380a022": "wintertime climate and host behaviors", | |
| "1e114659748f6405bcf3a07320758a9c5231ac2c063": "", | |
| "b89b0f4ef2db199134ff6d56dbd192222e3992d7004": "summer temperatures will not substantially limit pandemic growth", | |
| "27eb325d6a236140589dab611c37465dbb0bbb07040": "annual fluctuation in temperature relative to the season", | |
| "005c973a56fa231043d52c7cfd7d7ae062dcf93414": "both prevalence and incidence of COVID-2019", | |
| "240361c17d793375443d2ebe8d02a9091e5322c9142": "", | |
| "3d6e71763e324f71b113082961095a26d9854d3c011": "winter months", | |
| "229a0e76733d1b56a38c4c25b68bba80026a55c1020": "summer outbreaks would naturally have lower peaks than winter outbreaks", | |
| "f0b9d5f6245baed17d0bc7a06955ce096518f420050": "by summer weather, and that it 140 could return in autumn and pose increasing risks by winter", | |
| "cd1a30d9ab54604d2e277663cbc9ed650cd1cadc18": "85 % ethanol, efficiently inactivated the virus with reduction 22 factors (RFs) of \uf0a3 5.9", | |
| "eb3e5b7064260a4134b16971dfa18e66bd6a71e123": "Fig.9 2A) and 2-propanol", | |
| "f53cb4acd1ac85d4dbf6b50b063f97a2482cb35a24": "30 %", | |
| "32e3142d7cae316290aa96ae264df0ed5f3c39de163": "<100 \u00b0C", | |
| "679f2c4920c83244193203532c61ee131d881548192": "254 nm, 8 W lamp, and 475 cm 2 internal area", | |
| "426477b53e76f0e1d72235648f51eee3275d8c09083": "", | |
| "039d70b359128680c6984b4be077299b3d151842084": "", | |
| "426477b53e76f0e1d72235648f51eee3275d8c09085": "", | |
| "426477b53e76f0e1d72235648f51eee3275d8c09113": "", | |
| "426477b53e76f0e1d72235648f51eee3275d8c09116": "", | |
| "426477b53e76f0e1d72235648f51eee3275d8c09154": "40-50%", | |
| "4810fdc2ad909371fb1e98126410e3e028934f9b68": "", | |
| "a47d617328a3198efde2e1a90173f003a8cef38f066": "8 oral swabs positive", | |
| "2474e266cab77ea27b0448a56c0416a8e637ce45001": "", | |
| "c244fdbadbf24189fef4e73262a39fc5823f14e4051": "", | |
| "7b625b318bd332711a51cf2105155d3b70c9a0ef127": "1.1, p=0.61) and chronic bronchitis", | |
| "92576693c3d9929bc09cdcd3f34227b92867d41e10": "", | |
| "92576693c3d9929bc09cdcd3f34227b92867d41e56": "", | |
| "7fa733f5c80872c73275943889e095910006938c009": "10.0%", | |
| "7fa733f5c80872c73275943889e095910006938c044": "", | |
| "7fa733f5c80872c73275943889e095910006938c046": "", | |
| "7fa733f5c80872c73275943889e095910006938c077": "", | |
| "7fa733f5c80872c73275943889e095910006938c080": "Kaplan-Meier plot to analyze the length of hospitalization for all 291 patients (Figure 2 ), which shows a median length of 16 days", | |
| "7fa733f5c80872c73275943889e095910006938c092": "", | |
| "7fa733f5c80872c73275943889e095910006938c197": "", | |
| "7fa733f5c80872c73275943889e095910006938c204": "", | |
| "7fa733f5c80872c73275943889e095910006938c205": "", | |
| "7fa733f5c80872c73275943889e095910006938c207": "Hunan, China", | |
| "1e630ab92378ec9db87fffefe68ec7fbbb7128f4006": "", | |
| "1e630ab92378ec9db87fffefe68ec7fbbb7128f4026": "", | |
| "1e630ab92378ec9db87fffefe68ec7fbbb7128f4078": "", | |
| "1e630ab92378ec9db87fffefe68ec7fbbb7128f4148": "", | |
| "216b92af5ce42620e4f0a3ddf2021b6d2ea1ab7c002": "", | |
| "216b92af5ce42620e4f0a3ddf2021b6d2ea1ab7c018": "", | |
| "216b92af5ce42620e4f0a3ddf2021b6d2ea1ab7c035": "", | |
| "216b92af5ce42620e4f0a3ddf2021b6d2ea1ab7c037": "27.9%", | |
| "216b92af5ce42620e4f0a3ddf2021b6d2ea1ab7c090": "", | |
| "b84f73f5b97bdfdb0d0ca08b75c26cd5391dfb2f007": "1.70", | |
| "f4f02e8a97942a4221d75d32b385954338d70ce5128": "1.5-2 times greater risk.", | |
| "7f9b303bc68d0d42d89546560cc2f9d9a158f782177": "2.81", | |
| "2ad3a9084066cbabd3694754521328781a360441013": "3.69", | |
| "59e6ec6d42c0ec8e794209f06199afeab3c5b1f0070": "2.49", | |
| "11c5b058e866772567fb6dadbda54dab1ba9a9bf015": "1.58, 95%CI 1.07-2.32) and malignancy", | |
| "e7135a3f4c46826c406c86fccdd17156e2cf8f3c012": "", | |
| "1d8b1157da869240c4b1f5569d05d1c69723a6be012": "1.9", | |
| "45bfe696396f6654e203bfb151b0182f57b24e67105": "2.67", | |
| "75fe7da17583818448c0861668dda6c475311569122": "2.3", | |
| "45bfe696396f6654e203bfb151b0182f57b24e67122": "2.67", | |
| "31c99c5afed086622d7d9e761e252171415fed07215": "1.97, 95% CI 1.40 -2.77", | |
| "5792e89aeb83b4a0a3d22d4e559390613d90002239": "2.36", | |
| "850e600282dfbf81b4bf64a86970c4425c366785099": "2.69", | |
| "8424c03f8cd9e5bc929ff4635a7b84029272bbb1006": "2.72", | |
| "484eb165a91c8ed2f58edbcc98aa9481d8075b34006": "3.68", | |
| "a5e5315d03b1f9f3a20fd52096a5dc4cb3257bd2127": "", | |
| "be22ae73dcd716603ca39f9e014b35702c7b4af7127": "", | |
| "9cafdf98ac025864d2d74736e27bb9f223c8f0a823": "2.54", | |
| "277c5cf7e01a39eb3318726b0396a28345482d8f106": "significantly higher mortality rate", | |
| "d7524007e89c000d7356f2de7de08398e7ec55c5135": "OR = 3.04", | |
| "2efff625749dcb724fb369bf2ac8bfc6d4ab019d116": "2.45", | |
| "83ac4640a805feaf1c7219cfb548b7eef58d0c33011": "fasting blood glucose", | |
| "279e04a5af85e93be540346db28679829db3eb57064": "4.75" | |
| } | |